Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes
Launched by UMRANIYE EDUCATION AND RESEARCH HOSPITAL · May 13, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the levels of certain substances in the blood (called vasohibin-1, vasohibin-2, cardiotrophin-1, and endocan) during early pregnancy, specifically between the 11th and 14th weeks. Researchers want to see if these levels can help predict complications that might affect both the mother and her baby, such as preeclampsia, gestational hypertension, gestational diabetes, preterm birth, and growth issues in the baby.
To join this study, participants need to be pregnant women who are considered low-risk and have had their first-trimester screening test done between 11 and 14 weeks of pregnancy. Eligible women should be carrying only one baby and should not have serious health issues or any problems with their uterus. If chosen to participate, women will provide blood samples and may help researchers understand more about how these substances in the blood relate to healthy pregnancies. This research is important as it could lead to better ways to monitor and support mothers and babies during pregnancy.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
- • Those with singleton pregnancy
- • Those who did not conceive pregnancy with assisted reproductive treatment methods
- • Those who do not have any pregestational diseases
- • Those who do not have any uterine anomalies
- Exclusion Criteria:
- • Smokers
- • Those who are in the high-risk group with the first trimester screening test
- • Those with multiple pregnancies
- • Those who conceive with assisted reproductive treatment methods
- • Those who had any disease before pregnancy
- • Those who have any uterine anomalies
About Umraniye Education And Research Hospital
Umraniye Education and Research Hospital is a leading healthcare institution dedicated to advancing medical research and education. Located in Istanbul, Turkey, the hospital is renowned for its commitment to providing high-quality patient care while fostering innovation in clinical trials. As a clinical trial sponsor, Umraniye Education and Research Hospital emphasizes ethical standards, rigorous scientific methodology, and collaboration with healthcare professionals and researchers. The institution aims to contribute to the development of new therapies and improve health outcomes through its robust research programs and a multidisciplinary approach to clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, ümraniye, Turkey
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0